Repligen Co. (NASDAQ:RGEN) Shares Sold by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT trimmed its stake in Repligen Co. (NASDAQ:RGEN) by 1.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 5,936 shares of the biotechnology company’s stock after selling 78 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Repligen were worth $748,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. YHB Investment Advisors Inc. bought a new position in Repligen in the 1st quarter worth approximately $26,000. Andra AP fonden acquired a new position in Repligen during the 2nd quarter worth $25,000. Lazard Asset Management LLC grew its stake in shares of Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Repligen during the second quarter valued at $33,000. Finally, Principal Securities Inc. bought a new stake in shares of Repligen during the fourth quarter valued at about $48,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $190.00 target price on shares of Repligen in a research report on Wednesday, July 31st. UBS Group dropped their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Guggenheim started coverage on Repligen in a research note on Tuesday, June 18th. They set a “neutral” rating for the company. Benchmark reissued a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $188.38.

Repligen Stock Up 2.6 %

Shares of Repligen stock opened at $145.78 on Friday. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13. The firm has a market capitalization of $8.17 billion, a PE ratio of 583.14, a price-to-earnings-growth ratio of 4.14 and a beta of 0.94. The stock’s fifty day moving average is $146.96 and its 200-day moving average is $155.87.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same period in the prior year, the firm earned $0.53 earnings per share. The business’s quarterly revenue was down 3.2% on a year-over-year basis. Equities analysts anticipate that Repligen Co. will post 1.45 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.